China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
MALVERN, Pa., April 24, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase (JAK) inhibitors at the 76th Annual Society for Investigative Dermatology Meeting in Portland, Oregon. The symposium, titled “You Don’t Know JAK,” will be held on Thursday, April 27, 2017, from 12:00-1:45 PM PST. Poster presentations include:
- Clinical investigation of JAK inhibitor tofacitinib in scarring alopecias: Lindsey Bordone, MD, Columbia University, New York, NY, Abstract #075
- Treatment of vitiligo with topical Janus Kinase inhibitor ruxolitinib: Brooke Rothstein, Tufts Medical Center, Boston, MA, Abstract #770
- Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials: James Chen, PhD, Columbia University, New York, NY, Abstract #397
Dr. Neal Walker, President and Chief Executive Officer, and Dr. Stuart Shanler, Chief Scientific Officer, will be in attendance. Following the poster presentations, there will be a panel discussion and question and answer session with presenters.
Additional information on the 76th Annual Society of Investigative Dermatology Meeting can be found at: http://www.sidnet.org/news/339026/View-the-2017-Annual-Meeting-Program.htm
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
